The long search for a drug to slow the decline of Alzheimer’s may have reached a turning point. Pharmaceutical companies Biogen and Eisai have…
After years of failure, including some pharmaceutical companies calling off Alzheimer’s research altogether, Biogen offers a glimmer of hope: New data from a Phase…
Any Alzheimer’s drug under development has a complicated journey from formulation to clinical trials to potentially getting in the hands of patients. We spoke…
Another Alzheimer’s drug has failed in a phase 3 trial, the stage right before drugs go to the Food and Drug Administration for approval….